Related Stocks: DNDN H.S. Ayoub submits: A new study published in the peer reviewed publication Clinical Cancer Research found that human trials of the new class of cancer vaccines, which includes Dendreon's (DNDN) Provenge for prostate cancer, have been aiming for a primary endpoint that is irrelevant. Complete Story »
Categories
- About Flood Insurance
- Allstate Insurance Claim
- Articles
- Blogroll
- Commercial Vehicle Insurance
- Credit Insurance Company
- Directories
- Disability Benefits Insurance
- Friends
- Gadgets
- Home Insurance
- House Insurance
- In Car Insurance
- In Dental Insurance
- Insurance Claims
- Insurance Companies
- Insurance News
- International Health Insurance
- Liability Insurance
- Life Insurance
- Medical Insurance
- Pet Insurance
- Progressive Insurance
- Reinsurance
- State Farm Insurance
- Sun
- Taxes
- Travel Insurance
- Usefull Resources
- Whole Life Insurance
Search
Latest
- Ex-Cologne Re exec was told deal involved no risk
- House again fails to override Bush’s SCHIP veto
- Blue Cross proposes fix for uninsured Americans
- Dodd urges Senate flood insurance action
- Congress approves bill to expand FMLA for military families
- EU adopts major energy, climate change plan
- Ambac posts $3.3 billion loss
- Reinsurer moves carbon trading desk to London
- Berkshire buys stake in Swiss Re
- Risk issues top WEF agenda
Responses to 'Dendreon Jumps on New Cancer Vaccine Report'